Submission of audited standalone and consolidated financial results for the quarter as well year ended 31.03.2025 along with the auditor report, statement of assets and liabilities and cashflow.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Medi-Caps Ltd submitted its audited financial results for the quarter and full year ended 31 March 2025, with an unmodified (clean) opinion from statutory auditor Rawka & Associates. On a standalone basis, FY25 profit before tax fell sharply to Rs 28.50 Lacs from Rs 482.73 Lacs in FY24, while standalone revenue from operations dropped to Rs 241.66 Lacs from Rs 716.54 Lacs. On a consolidated basis (which includes wholly-owned pharma subsidiary Medgel Pvt Ltd), revenue declined modestly to Rs 2,547.71 Lacs from Rs 2,782.01 Lacs, and the company reported a loss before tax of Rs 84.11 Lacs, narrower than the Rs 124.60 Lacs loss in FY24. Consolidated net loss came in at Rs 57.10 Lacs versus Rs 224.03 Lacs in FY24. The company also re-appointed Praveen Shrivastava & Company as internal auditor for FY26.
The continued consolidated losses and the steep standalone earnings decline are negatives for shareholders, though the narrowing of losses and clean audit opinion provide some comfort. Existing investors should note weak profitability despite revenue from the pharma subsidiary, while the stock may remain volatile given the small scale and negative bottom line.